-
Saquinavir Workflows for HIV Protease Research
2026-08-27
Build a more informative Saquinavir workflow by pairing HIV protease inhibition with biomimetic membrane-partition measurements. IAM LC offers robust, scalable screening, while LEKC can better represent phospholipid-driven permeability behavior when the compound and assay conditions are compatible.
-
TCAIM Regulates OGDH and Mitochondrial Metabolism
2026-08-27
The 2025 Molecular Cell study identifies TCAIM as a mitochondrial DNAJC co-chaperone that selectively binds native OGDH and lowers its protein abundance through HSPA9 and LONP1. This noncanonical proteostasis mechanism suppresses OGDH complex activity and reshapes carbohydrate metabolism in cultured cells and murine models.
-
NADPH Oxidase ROS Activate L-Type Ca2+ Channels
2026-08-26
The reference study identifies L-type voltage-gated Ca2+ channels as the principal downstream mediator of NADPH oxidase-derived ROS in saphenous arteries from early postnatal rats. Pharmacological pathway dissection separates this mechanism from Rho-kinase, PKC, and Src-kinase signaling, while showing that calcium-channel blockade does not suppress ROS production.
-
Lactylation, NSUN2, and Perineural Invasion in PDAC
2026-08-26
This 2026 Theranostics study identifies NSUN2 K692 lactylation as a metabolic link between lactate accumulation and perineural invasion in pancreatic ductal adenocarcinoma. By combining genetic, RNA-epitranscriptomic, cell-based, and in vivo models, the authors define an NSUN2–m5C–CDCP1/STC1 axis that stabilizes pro-invasive transcripts and may offer a framework for studying neural dissemination.
-
Cy5 Hydrazide for Carbonyl Labeling Workflows
2026-08-25
Cy5 hydrazide converts protein, glycoprotein, oligonucleotide, and selected nanoparticle carbonyls into a bright far-red signal for quantitative analysis. Its strong optical response and SDS-PAGE compatibility are balanced by practical requirements for fresh DMSO dissolution, protected handling, and rigorous removal of unreacted dye.
-
ERAD-Hijacking Chimeras for Membrane Protein Degradation
2026-08-25
Song et al. establish ERAD-engaging chimeras (ERADECs), a small-molecule platform that redirects transmembrane proteins to endoplasmic-reticulum-associated degradation. By using desonide to engage the ER E3 ligase SYVN1, the study achieves highly efficient PD-L1 depletion and demonstrates therapeutic effects in tumor models.
-
Persistent rDNA Damage and PML-Nucleolar Compartments
2026-08-24
The reference study identifies persistent ribosomal DNA lesions, rather than generic genotoxic stress alone, as a key trigger of PML-nucleolar associations. By combining chemical stress, locus-specific I-PpoI cleavage, DNA-repair perturbation, and imaging, the authors connect topological stress and incomplete homologous recombination with rDNA compartmentalization and cellular senescence.
-
7ACC2: Mapping Lactate Flux in Tumor Immunity
2026-08-24
7ACC2 is a monocarboxylate transporter 1 inhibitor for resolving lactate and pyruvate flux in cancer models. This article connects transport-focused assay design with the 25-hydroxycholesterol–AMPK–STAT6 pathway in tumor-associated macrophages while separating established evidence from testable hypotheses.
-
Dual-mRNA LNPs Broaden Influenza Protection in Mice
2026-08-23
A Biomaterials study engineered lipid nanoparticles that co-deliver influenza hemagglutinin mRNA with either GIFT4 or CCL27 cytokine-adjuvant mRNA. In mice, this strategy strengthened humoral and systemic cellular immunity, promoted lung tissue-resident T cells, and improved protection against heterologous influenza A viruses after intradermal vaccination.
-
Topoisomerase I Controls Satellite DNA Transcription
2026-08-22
The 2024 Nature Communications study identifies Topoisomerase I as an evolutionarily conserved regulator of RNA Polymerase II transcription from centromeric α-satellite DNA. Its cellular, biochemical, and animal-model experiments connect TopI-dependent transcription with DNA-damage responses and provide a framework for studying repetitive non-coding DNA in chromosome biology.
-
Doxorubicin Hydrochloride: Liposome Workflows
2026-08-22
Build more reproducible doxorubicin cytotoxicity assays, apoptosis assays, and cardiotoxicity models with a controlled workflow for Doxorubicin hydrochloride. A nanoparticle-exclusion HPLC strategy also helps distinguish free from encapsulated Adriamycin HCl in dual-loaded liposomes.
-
Mitoxantrone HCl: DNA Damage Assay Workflows
2026-08-21
Mitoxantrone HCl supports more than conventional DNA-damage experiments: it enables Topo-II inhibition, apoptosis profiling, immune-cell studies, and emerging ERα resistance assays. This workflow-focused guide shows how to prepare, dose, interpret, and troubleshoot the compound across translational research models.
-
Podophyllotoxin Derivative 5p Overcomes MDR
2026-08-20
The reference study shows that podophyllotoxin derivative 5p combines catalytic topoisomerase IIα inhibition with suppression of microtubule polymerization. This dual mechanism reduced proliferation in drug-resistant breast and oral cancer models, altered drug-efflux transporter expression, promoted G2/M arrest and apoptosis-associated pyroptosis, and limited tumor growth in xenograft models.
-
Rimonabant (SR141716) for CB1 Research
2026-08-20
Rimonabant (SR141716) gives researchers a selective CB1 perturbation tool for separating appetite, inflammatory, cellular, and cannabinoid-withdrawal phenotypes from nonspecific toxicity. Its value is especially clear when paired with pathway controls in terpene analgesia and other endocannabinoid system studies.
-
Exo1: Mechanistic Leverage for TEV Research
2026-08-19
Exo1 offers translational researchers a mechanistically distinct way to interrogate Golgi–ER traffic, ARF1-dependent membrane dynamics, and the secretory contribution to tumor extracellular vesicle biology. This article places Exo1 in context with recent TEV-targeting research while defining what the tool can—and cannot yet—support in preclinical decision-making.